Select Page

The Infinium Global Research analyzes the Antithrombin Market over the period of 2018 to 2024. This report also provides detailed qualitative and quantitative analyses of the market dynamics, market size and future trends in global antithrombin market. It will help a lot of decision makers to develop strategies and find new opportunities in the global markets of antithrombin. The report covers market changing aspects including drivers, restraints, opportunities, and trends expected to encouragement the expansion of the antithrombin market during the period. The global antithrombin market is projected to grow at a CAGR of 5.0% over the forecast period of 2018-2024. In 2016, the market size of antithrombin was worth USD 440.0 million and it is anticipated to reach USD 720.0 million by 2024.

We are Now Including the Impact Analysis of the COVID-19 on this Premium Report and the Forecast Period of this Report shall be Revised to 2020-2026.

The Section on the Impact of COVID-19 on this Market is Included in the Report for Free. To Know More Request Sample of this Report:  https://www.infiniumglobalresearch.com/reports/sample-request/1258

Antithrombin is a protein in blood that functions as a naturally occurring blood thinner. It also helps against the clotting of the blood. Moreover, it works as a small protein that inactivates several enzymes of the coagulation process. Antithrombin is a glycoprotein produced by the liver and consists of 432 amino acids. It is a rare hereditary disorder, which generally comes when a patient suffers repeated arterial clotting and pulmonary embolism and repetitive intrauterine fetal death. The antithrombin activity and antigen tests are used to help find out what may be causing abnormal blood clots in your body.

Hereditary Antithrombin Deficiency, Extracorporeal Membrane Oxygenation is Primarily Driving the Global Antithrombin Market

Widespread of antithrombin for several medical conditions such as hereditary antithrombin deficiency, extracorporeal membrane oxygenation is primarily driving the global antithrombin market. The currently approved antiplatelet agent, clopidogrel, has satisfied some of these requirements and has played a large role in expanding the antithrombotic market over the past few years. However, the pharmaceutical industry has taken a huge effort to develop antithrombotic that functions by inhibiting key enzymes positioned at higher levels of the coagulation system. Additionally, the use of antithrombin with heparin will prove more beneficial in the treatment of the patients suffering from antithrombin disorders.

However, price concerns associated with antithrombin over alternatives is likely to restrain the growth of the antithrombin market. The increase in the adoption of newer technologies and advanced products in developing countries are providing huge growth opportunities for the key players in the antithrombin market. Moreover, research-based applications are gaining grip to discover new disease indications.

Get this Section as a Free Customization in the Report along with Discount on the Study: https://www.infiniumglobalresearch.com/reports/request-discount/1258

Europe is Expected to Be the Largest Regional Market for Antithrombin

Europe is expected to be the largest regional market for antithrombin followed by North America. Owing to the higher adoption of antithrombin therapies, Europe region is anticipated to be the leading region over the forecast period. The rising research and development activities in the second largest leading country North America especially in US is propelling the growth of the antithrombin market. However, Asia Pacific is expected to be the fastest-growing region over the upcoming years. An increasing number of mergers and acquisitions involving diagnostic consumables manufacturing companies and rapid product launches are the key trends in the market.

The leading players in the antithrombin market include rEVO Biologics Inc., Grifols, Shire plc., and CSL Limited. Among the leading companies, rEVO is the company focused on the development of innovative therapeutics. rEVO Biologics is merged with the LFB group which is the leading European biopharmaceutical company specialized in innovative biotherapies, marketing its medicinal products in more than 40 countries around the world.

Segments Make up the Antithrombin Industry

The report on global antithrombin market covers segments such as, application, source and formulation. On the basis of application, the global antithrombin market is categorized into therapeutics and research and diagnostics. On the basis of source, the global antithrombin market is categorized into human and goat milk. On the basis of formulation, the global antithrombin market is categorized into lyophilized and liquid.

Key Players and the Regions of the Antithrombin Industry

The report provides profiles of the companies in the global antithrombin market such as, Scripps Laboratories, Inc., Diapharma Group, Inc., Lee Bisolutions, Inc, Dem ilac, Inc, Octapharma AG, Kedrion S.p.A., CSL Limited, Shire plc, Grifols and rEVO Biologics, Inc..

Browse Detailed TOC, Description, and Companies Mentioned in Report @ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-antithrombin-market

Reasons to Buy this Report:

  • Comprehensive analysis of global as well as regional markets of the antithrombin.
  • Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2024.
  • Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
  • Infinium Global Research– Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.